Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 4/20 | 0.50 |
| ▸ | NMT2 | O60551 | 3/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.49 |
| ▸ | NPY4R | P50391 | 3/20 | 0.48 |
| ▸ | NPY1R | P25929 | 2/20 | 0.48 |
| ▸ | NPY2R | P49146 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641028 | 0.97 | CPB2 (0.50) | NMT1NMT2CPB2NPY4RNPY1R | |
| SCHEMBL22117559 | 0.94 | NMT1 (0.50) | NMT1NMT2CPB2NPY4RCHRNB2 | |
| SCHEMBL22117561 | 0.94 | NMT1 (0.50) | NMT1NMT2CPB2NPY4RCHRNB2 | |
| SCHEMBL22117473 | 0.93 | NMT1 (0.48) | NMT1NMT2CPB2NPY4RNPY1R | |
| SCHEMBL22117472 | 0.93 | NMT1 (0.48) | NMT1NMT2CPB2NPY4RNPY1R | |
| SCHEMBL29641218 | 0.92 | CPB2 (0.59) | NMT1NMT2CPB2 | |
| Hydrochloric Acid SCHEMBL31021010 | 0.92 | NPY4R (0.48) | NMT1NMT2CPB2NPY4RNPY1R | |
| SCHEMBL30528168 | 0.89 | NPY4R (0.45) | NMT1NMT2CPB2NPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL31021035 | 0.88 | NPY4R (0.44) | NMT1NMT2CPB2NPY4RNPY1R | |
| SCHEMBL31396825 | 0.86 | NPY4R (0.65) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250051389-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NMT1 2235/4885NMT2 1313/4885CPB2 137/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | NMT1 2324/4885NMT2 1490/4885CPB2 1110/4885 |
| US-20250051389-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | ARG2, OAT, PDF | NMT1 1728/4885NMT2 1056/4885CPB2 707/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NMT1 2235/4885NMT2 1313/4885CPB2 137/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | NMT1 1392/4885NMT2 1787/4885CPB2 558/4885 |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | NMT1 2320/4885NMT2 1260/4885CPB2 1668/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NMT1 3295/4885NMT2 2327/4885CPB2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.